10x Genomics preliminary Q3 revenue $151.7M, down 1% YoY; instruments revenue falls 46%

10x Genomics, Inc.

2024-Q3 EPS reported -$1.11 revenue$445,764,000

Revenue of ~$151.7M, down 1% YoY; instruments revenue $19.1M (-46%), consumables $126.2M (+10%), services $6.4M (+48%).
Americas revenue $87.8M (-11% YoY); EMEA $37.9M (+18%); APAC $26.0M (+15%).
CEO cites commercial reorganization disruption and cautious customer spending on capital equipment as key headwinds.
Cash and equivalents ~$398M as of Sept 30; full-year 2024 guidance to be discussed on October 29 earnings call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.